| Document |
Document Title |
|
WO/2021/012689A1 |
Disclosed herein are phenylthiophene sulfonamide compounds, pharmaceutical compositions, a preparation method therefor and use thereof. The compounds of the present invention are capable of effectively and selectively inhibiting Bcl-xL, ...
|
|
WO/2021/003433A1 |
The present disclosure provides sustained release compositions of (Z)-endoxifen and polymorphs and salts thereof and methods of making sustained release compositions of (Z)-endoxifen and polymorphs and salts thereof. The present disclosu...
|
|
WO/2020/257940A1 |
The present application provides furosemide analogues of the general formula Z having activity as anti-Aβ aggregation agents and/or as inhibitors of Aβ induced neuroinflammation. Formula Z These compounds are useful in preventing, dela...
|
|
WO/2020/256863A1 |
The present disclosure provides water-based well treatment fluids methods of using such fluids in treating subterranean formations to prevent swelling and/or migration of fines. The water-based well treatment fluid contains an aqueous co...
|
|
WO/2020/214399A9 |
A method of carrying out a metathesis reaction includes the combination of at least one alkene or non conjugated diene with a Ruthenium-based catalyst with an cyclic(alkyl)(amino)carbene ligand to form a reaction mixture, heating the rea...
|
|
WO/2020/244323A1 |
Disclosed are a preparation method for a cis-p-mentha-1,8-secondary amine compound and a herbicidal application thereof. The method comprises: using a cis-p-mentha-1,8-di-schiff base compound as a raw material, putting reducing agents in...
|
|
WO/2020/237806A1 |
The present invention relates to the field of organic synthesis. Provided is a preparation method for 4-fluorine-3-methoxyl-5-methylaniline hydrochloride. A synthetic route of the preparation method for 4-fluorine-3-methoxyl-5-methylanil...
|
|
WO/2020/241123A1 |
Provided is a production method that is for a water absorbent which can simultaneously provide satisfactory absorption against pressure (AAP) and gel bed permeability (GBP) without essentially requiring the use of an epoxy crosslinking a...
|
|
WO/2020/229014A1 |
The invention concerns a compound of Formula (I) or a salt thereof, wherein R1 is H, (C1-C3)alkyl or CF3; R2 is H, (C1-C3)alkyl or CF3; A is CH2COOH, XCH2COOCH2CH3, XCH2COOH, XCH2CH2NH2, where X is nitrogen or oxygen atom; Ar is an aroma...
|
|
WO/2020/220942A1 |
A compound, an organic electroluminescent device containing the compound, and an application thereof. The compound has a structure shown in (I).
|
|
WO/2020/223225A1 |
Described are compounds, compositions, and methods that include oxygenated aromatic amines, such as an aminophenol-, phenyl-p- phenylenediamine-, and diaminobenzene-based compound useful as antioxidants. The oxygenated aromatic amine inc...
|
|
WO/2020/212510A1 |
The present invention is directed to methods for the asymmetric synthesis of esketamine. The present invention is further directed to key intermediates in the asymmetric esketamine synthesis. In one embodiment, the invention is an asymme...
|
|
WO/2020/214692A1 |
Tertiary amine and quaternary ammonium compounds of Formula I and/or Formula II are provided. The present technology also provides compositions that include one or more of the compounds that may be useful for electronics processing (e.g....
|
|
WO/2020/210823A1 |
The invention features compounds and pharmaceutical compositions having anti-inflammatory properties. Also provided are methods of using the compounds or compositions of the invention for treating an inflammatory disorder in a subject in...
|
|
WO/2020/208139A1 |
The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.
|
|
WO/2020/202940A1 |
Provided is a catalytic mixture with sufficient catalytic efficiency, wherein pressure loss is small when the catalytic mixture fills a flow reactor and a reactive solution is caused to flow therethrough, and the catalytic efficiency and...
|
|
WO/2020/203580A1 |
The present invention provides a method for producing a hetero type monodisperse polyethylene glycol having a step (A) for subjecting a compound of formula (2) and a compound of formula (3) to a nucleophilic substitution reaction so as t...
|
|
WO/2020/203444A1 |
A compound which has, between end groups arranged at both ends and each having a reactive group, a first structure wherein an aromatic ring group, an ether oxygen atom, a methylene group, an aromatic ring group, a methylene group, an eth...
|
|
WO/2020/194326A1 |
The present invention relates to a process for the preparation of tapentadol and analogs or compounds or stereoisomers of formula (I), Formula I wherein, A is aryl, heteroaryl, and cycloalkyl; R is H, OH, OR1, halogen, C1-C12 alkyl, cycl...
|
|
WO/2020/185872A1 |
Formamide group-containing monomers and polymers made by polymerizing the monomers are provided. Also provided are methods of polymerizing the monomers and methods of synthesizing functionalized polymers by pre- and/or post-polymerizatio...
|
|
WO/2020/167855A1 |
Useful processes of preparation and intermediates useful for the preparation of Compound 1, a selective estrogen receptor alpha (ERα) modulator/degrader (SERM/SERD), having utility for the treatment of ER+ cancers including breast cance...
|
|
WO/2020/156522A1 |
Provided are a dezocine derivative of formula I or a tautomer, optical isomer, oxynitride, solvate, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutical composition comprising the same, a preparation method therefor,...
|
|
WO/2020/158925A1 |
A method for producing a nitroso compound of formula (3), which comprises a process for reacting a compound of formula (1) and a compound of formula (2) with each other by using a tertiary alcohol and a base. (In the formulae, each of R1...
|
|
WO/2020/158523A1 |
The purpose of the present invention is to provide a diamine compound that can yield a resin that has both excellent solvent solubility (solution processability) and high heat resistance, a polyimide synthesized from said diamine compoun...
|
|
WO/2020/138398A1 |
The present invention addresses the problem of providing a novel compound exhibiting a high LSD1-inhibiting activity, high selectivity for LSD1 inhibition, and/or having a useful therapeutic effect for various diseases. One embodiment pe...
|
|
WO/2020/126819A1 |
The present invention relates to a process for preparing compounds of the formula (I), starting from compounds of the formula (II), wherein R1, R2, R3 and R3' are defined according to the invention.
|
|
WO/2020/121667A1 |
An ammonium salt having a saccharin anion, which is represented by formula (1), exhibits excellent thermal stability even though no halogen atom is contained therein. (In the formula, each of R1-R4 independently represents an alkyl group...
|
|
WO/2020/119147A1 |
Disclosed are a bicomponent epoxy mortar for pasting PVC and treating concrete expansion joints, a preparation method therefor and the use thereof. The raw materials of the epoxy mortar comprise a component A and a component B. The raw m...
|
|
WO/2020/121326A1 |
The present invention provides an amorphous form of (rac)-tramadol.HCl-celecoxib (1:1) and a solid dispersion and processes for the preparation of the same.
|
|
WO/2020/106933A1 |
The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and co...
|
|
WO/2020/104648A2 |
A compound of formula (I) with improved TGFβ signaling pathway inhibitory activity, improved therapeutic efficacy and improved toxicity profile, as well as two prodrugs thereof are disclosed. Compositions comprising said TGFβ signaling...
|
|
WO/2020/090989A1 |
In a production method for a fluorinated aromatic secondary or tertiary amine compound having a fluoroaryl moiety in a molecule, the method comprising reacting a fluorinated aromatic primary amine compound with a chlorinated, brominated,...
|
|
WO/2020/084599A2 |
The present invention relates to ammonium salts of partially fluorinated organic acids, represented by the general formula 1. The present invention relates also to a synthesis method of said salts as well as its use to the production of ...
|
|
WO/2020/068262A1 |
The present disclosure provides a polyetheramine produced from a cyclic amide initiator which is first alkoxylated and then reductively aminated to form the polyetheramine. The polyetheramine of the present disclosure may be used in a va...
|
|
WO/2020/057274A1 |
Provided is a method for preparing a substituted primary amine, using benzonitrile and its derivatives as a raw material, nano porous palladium as a catalyst, and hydrogen gas as a hydrogen source, so as to prepare the substituted primar...
|
|
WO/2020/052647A1 |
Involved are a class of spiro-heterocyclic compounds which can act as lysine-specific demethylase 1 (LSD1) inhibitors, and the use of same in the preparation of drugs for treating LSD1-related diseases. Specifically involved are a compou...
|
|
WO/2020/046515A1 |
The present disclosure provides a quaternary ammonium hydroxide solution comprising a reaction product of a polyamine and an organic oxirane. The quaternary ammonium hydroxide solution may be used in various applications, such as in remo...
|
|
WO/2020/044416A1 |
A copper sulfate plating solution which contains a compound containing at least a nitrogen atom, a hydrogen atom and a carbon atom, the copper sulfate plating solution being characterized in that the compound is such a compound that the ...
|
|
WO/2020/039456A1 |
The present invention provides a novel 1:1 co-crystal of (rac)-tramadol hydrobromide-celecoxib and processes for the preparation of the same by reacting (rac)-tramadol with hydrobromic acid and celecoxib. It also provides crystalline for...
|
|
WO/2020/040614A1 |
The present invention provides: a preparation method for a (3R,5R)-7-[2-(4-flurophenyl)-5-isopropyl-3-phenyl-4-[(4-hydr
oxymethylphenylamino)carbonyl]-pyrrrol-1-yl]-3,5-dihydroxy heptanoic acid hemicalcium salt; an intermediate used ther...
|
|
WO/2020/036069A1 |
Provided are: a composition for forming a hole transporting layer for perovskite solar cells, which is inexpensive and does not need to be used together with a dopant; and a compound which can be contained in a composition for forming a ...
|
|
WO/2020/032080A1 |
Provided is a compound represented by general formula (I), or a salt thereof. (In the formula, X1, X2, X3 and X4 are a hydrogen atom, a C1-9 alkyl group, or a C3-9 unsaturated hydrocarbon group which has 1-4 triple bonds between carbon a...
|
|
WO/2020/020064A1 |
Disclosed in the present invention is a method for safely preparing pimavanserin and a tartrate salt thereof using triphosgene. The synthesis routes comprise (1), (2), (3), (4) and (5). The raw materials used in the method of the present...
|
|
WO/2020/014606A1 |
Described are compositions and methods for inhibiting polymerization of a monomer (e.g., styrene) composition a quinone methide polymerization retarder and an oxygen-containing amine compound that is a tertiary amine or hydroxylamine. In...
|
|
WO/2020/010216A1 |
Various polymorphic forms of RAD1901-2HCI, including four crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCI for cancer treatment are also disclosed.
|
|
WO/2020/008052A1 |
The present invention relates to a compound of the following formula (I): (I). The invention also relates to uses thereof as dye or pigment, notably as a luster pigment. The invention relates also to a reflective or photonic or nanophoto...
|
|
WO/2020/002162A1 |
The present invention relates to an esteramine salt according to the general formula (I): The substituents R1, R2 and R3 are defined below. The present invention further relates to a process for preparing such an esteramine salt accordin...
|
|
WO/2020/002733A1 |
The present invention relates to the use of organic compounds for the treatment of the infection caused by the HIV-1 human immunodeficiency virus, as well as other diseases caused by RNA viruses.
|
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2020/006367A1 |
The invention provides methods and compositions for use in the prevention and treatment of antipsychotic medication-induced metabolic syndrome (MetS) and diseases and conditions related to MetS.
|
